Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Eye disorders – page 12

  • 369 clinical trials
  • 123 recruiting
  • 134 conditions
  • 27 countries

Conditions in this area

134 conditions with trials, the busiest first

Conjunctivitis allergic34Sjogren's syndrome29Endocrine ophthalmopathy26Neovascular age-related macular degeneration23Giant cell arteritis18Seasonal allergy17Uveal melanoma17Rhinitis allergic16Dry age-related macular degeneration15Diabetic retinal oedema13Dry eye12Retinitis pigmentosa11Age-related macular degeneration10Asthma10Graves' disease10Myopia10Glaucoma8Open angle glaucoma8Uveitis8Immunoglobulin G4 related disease7Behcet's syndrome6Cataract6Mite allergy6Rheumatoid arthritis6+110

Clinical trials in Eye disorders

369 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

369 clinical trials

Neovascular age-related macular degeneration

Not yet recruiting

Safety and Efficacy of Two Doses of OCUL101 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:65+ years
  • Substances:Aflibercept

Choroid melanoma

Not yet recruiting

Long‑Term Follow‑Up Study of Belzupacap Sarotalocan in Patients with Early Choroidal Melanoma

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Belzupacap Sarotalocan
  • Sponsor:Aura Biosciences Inc.

Sjogren's syndrome

Not yet recruiting

Efficacy and safety of efgartigimod alfa in adults with Sjögren’s disease‑associated sensorimotor or sensory polyneuropathy: a phase 2 randomized placebo‑controlled study

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Stargardt's disease

Not yet recruiting

Phase 3 Study of Gildeuretinol Acetate (ALK‑001) to Assess Safety and Efficacy in Slowing Progression of Stargardt Disease in Adults

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years

Conjunctivitis allergic+1

Not yet recruiting

Diagnostic Accuracy of Parietaria judaica Pollen Extract (SPT‑RX) in a Skin Prick Test Drug Combination for Adults with Allergic Rhinitis and Controlled Mild Asthma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Betula Pendula Pollen Extract
  • Sponsor:ROXALL Medizin GmbH

Neovascular age-related macular degeneration

Not yet recruiting

A Phase 2 Study of Aganirsen Eye Drops to Extend Intravitreal Aflibercept Injection Interval in Patients with Wet Age‑Related Macular Degeneration

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept

Neuromyelitis optica spectrum disorder+1

Not yet recruiting

Two dosing schedules of the herpes zoster vaccine (recombinant varicella zoster virus glycoprotein E) in MS and NMOSD patients on rituximab or ocrelizumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Dry age-related macular degeneration+1

Not yet recruiting

Safety, tolerability and exploratory efficacy of PST-611 in patients with geographic atrophy secondary to age-related macular degeneration

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Sponsor:PulseSight Therapeutics

Retinopathy of prematurity

Not yet recruiting

Intranasal Dexmedetomidine for Pain Relief During Retinopathy of Prematurity Screening in Preterm Infants <30 Weeks Gestation Using Standard Drug Combination

Registered drug
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Dexmedetomidine
  • Sponsor:St. Olavs Hospital HF

Conjunctivitis allergic+3

Not yet recruiting

Clinical Trial of Dermatophagoides farinae, Dermatophagoides pteronyssinus, and Blomia tropicalis Allergen Extracts in Patients with Allergic Rhinitis/Rhinoconjunctivitis With or Without Mild Asthma

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ALLERGEN EXTRACTS
  • Sponsor:Inmunotek S.L.

Seasonal allergy

Not yet recruiting

Dose-finding study of sublingual immunotherapy with phleum pratense extract (vs sodium chloride) in patients with grass pollen allergic rhinitis

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Phleum Pratense
  • Sponsor:Asac Pharmaceutical Inmunology S.A.

Substances studied in this area

The therapies tested most often in Eye disorders trials.

Aflibercept27 clinical trialsSodium Chloride16 clinical trialsPrednisone14 clinical trialsRanibizumab14 clinical trialsDexamethasone11 clinical trialsDexamethasone Phosphate10 clinical trialsFluorescein Sodium10 clinical trialsPrednisolone10 clinical trialsNivolumab8 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.